EP Patent

EP1848402B1 — Rasagiline formulations of improved content uniformity

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2016-05-11 · 10y expired

What this patent protects

Patent listed against rasagiline-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP1848402B1
Jurisdiction
EP
Classification
Expires
2016-05-11
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.